Thai Breast Disease Society

03/06/2026

03/06/2026

From emerging treatment strategies to survivorship research, catch up on some of the latest breast cancer research findings that stood out over the weekend.

03/06/2026

From chemotherapy de-escalation and oral SERDs to metastatic triple-negative breast cancer and GLP-1 medicines, Eleonora Teplinsky, MD breaks down some of the biggest breast cancer research updates from , what they could mean for breast cancer care, and the questions researchers are still working to answer.

31/05/2026

Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker with the potential to detect minimal residual disease (MRD), monitor treatment response, and identify recurrence (eg, molecular relapse) earlier than conventional clinical or imaging approaches.

Although ctDNA-based MRD assays have demonstrated prognostic value in early breast cancer, their optimal clinical utility remains uncertain.

This Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.

https://ja.ma/3PAJIRb

19/05/2026

In a patient-level meta-analysis reported in The Lancet, the Early Breast Cancer Trialists’ Collaborative Group found that ovarian function suppression (OFS) with ablation or drugs was associated with reduced 15-year risk of recurrence or death irrespective of chemotherapy or tamoxifen use in premenopausal women with estrogen receptor (ER)-positive early breast cancer.

19/05/2026

At Mayo Clinic Rochester, omission of sentinel lymph node surgery increased over time among selected patients with low-risk breast cancer, without a corresponding increase in radiation therapy or whole-breast irradiation: ASBrS 27th Annual Meeting UPDATE

ref: Hager MG, et al: Impact of omission of sentinel lymph node surgery on radiation treatment in patients age 50 and older with breast cancer treated with lumpectomy. Presented at the ASBrSs Virtual Press Briefing. April 23, 2026.

19/05/2026

In a select group of women with early-stage breast cancer, robotic ni**le-sparing mastectomy using showed an early safety profile comparable to the traditional open approach, according to findings presented by Katherine Kopkash, MD, FACS, Director of Oncoplastic Breast Surgery at Endeavor Health and Clinical Professor of Surgery at the University of Chicago Pritzker School of Medicine: ASBrS 27th Annual Meeting UPDATE

ref: Kopkash K: A prospective, multi-center randomized controlled trialof the da Vinci SP® Surgical System vs open surgery in ni**le sparing mastectomy. Presented at the ASBrS Press Briefing. April 23, 2026.

19/05/2026

A supervised 12-week resistance training program produced meaningful functional gains in breast cancer survivors, including those who had undergone mastectomy or axillary lymph node dissection, groups for whom upper-extremity loading has historically been restricted: ASBrS 27th Annual Meeting UPDATE

ref: Hernandez LC, et al: Functional outcomes for breast cancer survivors following an intense resistance training program based on surgical management of the breast and axilla. ASBrS Press Briefing. April 23, 2026.

19/05/2026

Young women with high-risk breast cancer who underwent breast-conserving surgery after neoadjuvant systemic therapy had outcomes similar to those who underwent mastectomy, according to findings from the I-SPY2 clinical trial: ASBrS 27th Annual Meeting UPDATE

ref: Tseng J, et al:. Surgical management of young women with high-risk breast cancer receiving neoadjuvant systemic therapy. Presented at the American Society of Breast Surgeons(ASBrS)Press Briefing. April 23, 2026.